Background <p>Growing evidence indicates that the pre-operative ratio of fibrinogen to albumin (FAR/AFR) can act as a prognostic predictor for different kinds of cancer. Although a previous meta-analysis briefly involved urological malignancies, it only incorporated one study for bladder cancer (BC) and one for renal cell carcinoma (RCC) with limited data. To date, a comprehensive and systematic quantitative assessment of plasma FAR/AFR as a prognostic indicator in urological cancers remains lacking.</p> Objective <p>This meta-analysis intended to comprehensively investigate the prognostic significance of plasma FAR/AFR in individuals with urological malignancies.</p> Methods <p>A thorough search of the PubMed, Embase, and Web of Science databases was carried out up to March 2026, leading to the incorporation of 6 studies for this meta-analysis. The research computed hazard ratios (HRs) together with their 95% confidence intervals (CIs) to evaluate disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS).</p> Results <p>The study included a total of 1,603 participants. Patients suffering from RCC and BC who showed an increase in pre-operation FAR or a decrease in pre-operation AFR had poorer overall survival (combined HR = 2.36, 95% CI = 1.92–2.91; <i>p</i> &lt; 0.001), cancer-specific survival (combined HR = 2.27, 95% CI = 1.77–2.91; <i>p</i> = 0.003), and disease-free survival (combined HR = 2.32, 95% CI = 1.62–3.31; <i>p</i> &lt; 0.001).Analysis based on cancer type showed that an increased pre-surgical FAR or a decreased pre-surgical AFR was associated with poorer overall survival in RCC) (combined HR = 3.19, 95% CI = 1.84–5.54, <i>p</i> &lt; 0.001) and also in BC (combined HR = 2.25, 95% CI = 1.80–2.81, <i>p</i> &lt; 0.001).</p> Conclusions <p>Increased FAR or decreased AFR act as independent markers of unfavorable survival prognosis in patients with RCC and BC.</p>